The widespread perception that it was once official British policy to let the novel coronavirus spread until the population reached herd immunity is false; the government was just overly optimistic about how easy flattening the curve would be. (Update, Apr 29: actually, no—herd immunity was indeed the plan, according to a new investigation by the Guardian.) But the idea has gained so much traction in some circles, fueled by speculation that we might already be much closer to it than we think, that it’s worth understanding why it’s not a viable policy according to the evidence to date.
More on coronavirus
Our most essential coverage of covid-19 is free, including:
Newsletter: Coronavirus Tech Report
Zoom show: Radio Corona
First, even assuming people who get sick do become immune, we have no idea how long they’ll stay immune. (With some coronaviruses, as well as with ordinary flu, immunity lasts less than a year.) Second, assuming they stay immune, we have no idea how long it would take to reach herd immunity.
The latter uncertainty stems from a few big, though related, unknowns. First, how contagious is the virus? The more contagious it is—measured as R0, the average number of people that a victim passes the virus on to—the more people need to be immune for the infection rate to start falling. But estimates of R0 vary. These estimates suggest that anywhere from about half to three-quarters of the population has to catch it.
Second, how many people have actually been infected so far? These estimates vary even more. One study from the team at Imperial College estimated that on March 28, when Italy had just under 100,000 known cases, or less than 0.2% of the population, the virus had actually infected some 10% of Italians, most of whom either had no symptoms or didn’t feel sick enough to get tested. That 50-fold difference is far bigger than some other estimates assume.
Third, what proportion of infected people never have symptoms? The official line from the US Centers for Disease Control is that it’s 25%, but small studies of some localized outbreaks have suggested it might be nearer 50%. Those would support the theory that the virus is already much more widespread.
But such figures remain highly disputed because we simply aren’t testing enough people to know how many infections there really are. And even if there are far more than we think, it’s still not clear that we’d reach natural herd immunity sooner than we can develop a vaccine or a cure. Either way, we still have to keep the infection rate down in the meantime to a level that doesn’t collapse the hospital system and leave an entire generation of health-care workers severely traumatized.
Biotechnology and health
Scientists are finding signals of long covid in blood. They could lead to new treatments.
Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests.
The first gene-editing treatment: 10 Breakthrough Technologies 2024
Sickle-cell disease is the first illness to be beaten by CRISPR, but the new treatment comes with an expected price tag of $2 to $3 million.
This baby with a head camera helped teach an AI how kids learn language
A neural network trained on the experiences of a single young child managed to learn one of the core components of language: how to match words to the objects they represent.
We’ve never understood how hunger works. That might be about to change.
Scientists have spent decades trying to unravel the intricate mysteries of the human appetite. Are they on the verge of finally determining how this basic drive functions?
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.